secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001077183-26-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q4 revenue up 11% to $190M; full-year net loss widens to $108M; RaDaR ST MRD launch imminent
--------------------------------------------------------------------------------

- Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.
- Q4 net loss decreased 36% to $10M; full-year net loss increased 37% to $108M; Adjusted EBITDA positive $13M (Q4) and $43M (FY).
- Clinical NGS volumes grew 23% in Q4 and 22% for full year, outpacing market growth.
- RaDaR ST MRD assay imminent clinical launch; company addresses $20B+ MRD monitoring market; modest 2026 revenue expected.
- Successfully resolved RaDaR ST patent litigation (no financial details disclosed).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000004/0001077183-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000004/neo-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001077183-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer